Elanco Animal Health (ELAN) Tops Q3 EPS by 4c, Revenues Miss; Offers FY18 EPS Outlook Above Consensus,
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Elanco Animal Health Reports Strong Third Quarter Results, Provides Financial Guidance for Full Year 2018
November 6, 2018 6:02 AM ESTThird quarter revenue grew 9 percent to $761.1 million. Revenue, excluding strategic exits, grew 13 percent to $733.4 million; removing the impact of foreign currency exchange rates, growth was 15 percent. Reported net income grew $80.9 million in the third quarter to $60.2 million, which represents $0.16 per diluted share and $0.29 per diluted share on an adjusted basis. Delivered Innovation, including launching Prevacent® PRRS, a swine vaccine, and CorrelinkTM, a nutritional health product for poultry, as well as signing a licensing agreement with Novozymes to... More
